How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

News headlines Recursion Pharmaceuticals (RXRX) is gaining attention due to its promising clinical trials and AI-driven drug discovery. Recent upgrades from JPMorgan and insights into its valuation ...

With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly.